Advertisement

Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer

  • Nader Aboul-Fettouh
    Affiliations
    Department of Dermatology, McGovern Medical School at the University of Texas Health Science Center at Houston, 6655 Travis St., #980 Houston, TX 77030, USA
    Search for articles by this author
  • Shelby L. Kubicki
    Affiliations
    Department of Dermatology, McGovern Medical School at the University of Texas Health Science Center at Houston, 6655 Travis St., #980 Houston, TX 77030, USA
    Search for articles by this author
  • Leon Chen
    Affiliations
    US Dermatology Partners, 1213 Hermann Dr #650, Houston, TX 77004, USA

    Elite Dermatology, 20326, TX-249 Ste 400, Houston, TX 77070, USA
    Search for articles by this author
  • Sirunya Silapunt
    Affiliations
    Department of Dermatology, McGovern Medical School at the University of Texas Health Science Center at Houston, 6655 Travis St., #980 Houston, TX 77030, USA
    Search for articles by this author
  • Michael R. Migden
    Correspondence
    Corresponding author. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, 1452, Houston, TX 77030.
    Affiliations
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street., 1452, Houston, TX 77030, USA

    Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, 1452, Houston, TX 77030, USA
    Search for articles by this author
Published:October 27, 2022DOI:https://doi.org/10.1016/j.det.2022.07.009

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leiter U.
        • Eigentler T.
        • Garbe C.
        Epidemiology of skin cancer.
        Adv Exp Med Biol. 2014; 810: 120-140
        • Oda K.
        • Matsuoka Y.
        • Funahashi A.
        • et al.
        A comprehensive pathway map of epidermal growth factor receptor signaling.
        Mol Syst Biol. 2005; 1: 2005.0010
        • Tran Q.T.
        • Kennedy L.H.
        • Leon Carrion S.
        • et al.
        EGFR regulation of epidermal barrier function.
        Physiol Genomics. 2012; 44: 455-469
        • Cañueto J.
        • Cardeñoso E.
        • García J.L.
        • et al.
        Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma.
        Br J Dermatol. 2017; 176: 1279-1287
        • Chanprapaph K.
        • Vachiramon V.
        • Rattanakaemakorn P.
        Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.
        Dermatol Res Pract. 2014; 2014: 734249
        • Skoda A.M.
        • Simovic D.
        • Karin V.
        • et al.
        The role of the Hedgehog signaling pathway in cancer: a comprehensive review.
        Bosn J Basic Med Sci. 2018; 18: 8-20
        • Stecca B.
        • Pandolfi S.
        Hedgehog-Gli signaling in basal cell carcinoma and other skin cancers: prospects for therapy.
        Res Rep Biol. 2015; 6: 55-71
        • Carpenter R.L.
        • Ray H.
        Safety and tolerability of sonic hedgehog pathway inhibitors in cancer.
        Drug Saf. 2019; 42: 263-279
        • Riley J.L.
        PD-1 signaling in primary T cells.
        Immunol Rev. 2009; 229: 114-125
        • Robainas M.
        • Otano R.
        • Bueno S.
        • et al.
        Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy.
        Onco Targets Ther. 2017; 10: 1803-1807
        • Akinleye A.
        • Rasool Z.
        Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
        Hematol Oncol. 2019; 12: 92
        • Brahmer J.R.
        • Tykodi S.S.
        • Chow L.Q.M.
        • et al.
        Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
        N Engl J Med. 2012; 366: 2455-2465
        • Baraibar I.
        • Melero I.
        • Ponz-Sarvise M.
        • et al.
        Safety and tolerability of immune checkpoint inhibitors (Pd-1 and pd-l1) in cancer.
        Drug Saf. 2019; 42: 281-294
        • Wu S.
        • Han J.
        • Li W.-Q.
        • et al.
        Basal-cell carcinoma incidence and associated risk factors in U.S. women and men.
        Am J Epidemiol. 2013; 178: 890-897
        • Lo J.S.
        • Snow S.N.
        • Reizner G.T.
        • et al.
        Metastatic basal cell carcinoma: report of twelve cases with a review of the literature.
        J Am Acad Dermatol. 1991; 24: 715-719
        • Seo S.-H.
        • Shim W.-H.
        • Shin D.-H.
        • et al.
        Pulmonary metastasis of Basal cell carcinoma.
        Ann Dermatol. 2011; 23: 213-216
        • Pfeiffer P.
        • Hansen O.
        • Rose C.
        Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature.
        Eur J Cancer. 1990; 26: 73-77
        • Moeholt K.
        • Aagaard H.
        • Pfeiffer P.
        • et al.
        Platinum-Based Cytotoxic Therapy in Basal Cell Carcinoma a review of the literature.
        Acta Oncol. 1996; 35: 677-682
        • Jefford M.
        • Kiffer J.D.
        • Somers G.
        • et al.
        Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.
        ANZ J Surg. 2004; 74: 704-705
        • Chatelut E.
        • Delord J.-P.
        • Canal P.
        Toxicity patterns of cytotoxic drugs.
        Invest New Drugs. 2003; 21: 141-148
        • Sekulic A.
        • Migden M.R.
        • Basset-Seguin N.
        • et al.
        Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
        BMC cancer. 2017; 17: 332
        • Basset-Séguin N.
        • Hauschild A.
        • Kunstfeld R.
        • et al.
        Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
        Eur J Cancer. 2017; 86: 334-348
        • Dréno B.
        • Kunstfeld R.
        • Hauschild A.
        • et al.
        Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (Mikie): a randomised, regimen-controlled, double-blind, phase 2 trial.
        Lancet Oncol. 2017; 18: 404-412
        • Dummer R.
        • Lear J.T.
        • Guminski A.
        • et al.
        Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months.
        J Am Acad Dermatol. 2021; 84: 1162-1164
        • Pricl S.
        • Cortelazzi B.
        • Dal Col V.
        • et al.
        Smoothened (Smo) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
        Mol Oncol. 2015; 9: 389-397
        • Ikeda S.
        • Goodman A.M.
        • Cohen P.R.
        • et al.
        Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.
        NPJ Genom Med. 2016; 1: 16037
        • Omland S.H.
        • Nielsen P.S.
        • Gjerdrum L.M.R.
        • et al.
        Immunosuppressive environment in basal cell carcinoma: the role of regulatory t cells.
        Acta Derm Venereol. 2016; 96: 917-921
        • Jayaraman S.S.
        • Rayhan D.J.
        • Hazany S.
        • et al.
        Mutational landscape of basal cell carcinomas by whole-exome sequencing.
        J Invest Dermatol. 2014; 134: 213-220
        • Deng J.S.
        • Brod B.A.
        • Saito R.
        • et al.
        Immune-associated cells in basal cell carcinomas of skin.
        J Cutan Pathol. 1996; 23: 140-146
        • Urosevic M.
        • Dummer R.
        Immunotherapy for nonmelanoma skin cancer: does it have a future?.
        Cancer. 2002; 94: 477-485
        • Berg D.
        • Otley C.C.
        Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management.
        J Am Acad Dermatol. 2002; 47 ([quiz: 18-20]): 1-17
        • Aboul-Fettouh N.
        • Chen L.
        • Silapunt S.
        • et al.
        Use of pd-1 inhibitors in the treatment of advanced basal cell carcinoma.
        Dermatol Surg. 2021; 47: 1511-1512
        • Stratigos A.J.
        • Sekulic A.
        • Peris K.
        • et al.
        Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
        Lancet Oncol. 2021; 22: 848-857
        • Chang A.L.S.
        • Tran D.C.
        • Cannon J.G.D.
        • et al.
        Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.
        J Am Acad Dermatol. 2019; 80: 564-566
        • Schmults C.D.
        • Karia P.S.
        • Carter J.B.
        • et al.
        Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study.
        JAMA Dermatol. 2013; 149: 541-547
        • Brewster D.H.
        • Bhatti L.A.
        • Inglis J.H.C.
        • et al.
        Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992-2003.
        Br J Dermatol. 2007; 156: 1295-1300
        • Andersson E.M.
        • Paoli J.
        • Wastensson G.
        Incidence of cutaneous squamous cell carcinoma in coastal and inland areas of Western Sweden.
        Cancer Epidemiol. 2011; 35: e69-e74
        • Katalinic A.
        • Kunze U.
        • Schäfer T.
        Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (Epidemiology of skin cancer).
        Br J Dermatol. 2003; 149: 1200-1206
        • DeConti R.C.
        Chemotherapy of squamous cell carcinoma of the skin.
        Semin Oncol. 2012; 39: 145-149
        • Sadek H.
        • Azli N.
        • Wendling J.L.
        • et al.
        Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin.
        Cancer. 1990; 66: 1692-1696
        • Guthrie T.H.
        • McElveen L.J.
        • Porubsky E.S.
        • et al.
        Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin.
        Cancer. 1985; 55: 1629-1632
        • Maubec E.
        • Boubaya M.
        • Petrow P.
        • et al.
        Phase ii study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas.
        J Clin Oncol. 2020; 38: 3051-3061
        • Montaudié H.
        • Viotti J.
        • Combemale P.
        • et al.
        Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study.
        Oncotarget. 2020; 11: 378-385
        • William W.N.
        • Feng L.
        • Ferrarotto R.
        • et al.
        Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.
        J Am Acad Dermatol. 2017; 77: 1110-1113.e2
        • Gold K.A.
        • Kies M.S.
        • William W.N.
        • et al.
        Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
        Cancer. 2018; 124: 2169-2173
        • Wheeler D.L.
        • Dunn E.F.
        • Harari P.M.
        Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
        Nat Rev Clin Oncol. 2010; 7: 493-507
        • Pickering C.R.
        • Zhou J.H.
        • Lee J.J.
        • et al.
        Mutational landscape of aggressive cutaneous squamous cell carcinoma.
        Clin Cancer Res. 2014; 20: 6582-6592
        • Euvrard S.
        • Kanitakis J.
        • Claudy A.
        Skin cancers after organ transplantation.
        N Engl J Med. 2003; 348: 1681-1691
        • Wu Y.
        • Xu J.
        • Du C.
        • et al.
        The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis.
        Front Oncol. 2019; 9: 1161
        • Amoils M.
        • Kim J.
        • Lee C.
        • et al.
        Pd-l1 expression and tumor-infiltrating lymphocytes in high-risk and metastatic cutaneous squamous cell carcinoma.
        Otolaryngol Head Neck Surg. 2019; 160: 93-99
        • Migden M.R.
        • Rischin D.
        • Schmults C.D.
        • et al.
        PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
        N Engl J Med. 2018; 379: 341-351
        • Hughes B.G.M.
        • Munoz-Couselo E.
        • Mortier L.
        • et al.
        Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
        Ann Oncol. 2021; 32: 1276-1285
        • Nowicki T.S.
        • Hu-Lieskovan S.
        • Ribas A.
        Mechanisms of resistance to pd-1 and pd-l1 blockade.
        Cancer J. 2018; 24: 47-53
        • Upadhaya S.
        • Neftelino S.T.
        • Hodge J.P.
        • et al.
        Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.
        Nat Rev Drug Discov. 2021; 20: 168-169
        • Puzanov I.
        • Milhem M.M.
        • Andtbacka R.H.I.
        • et al.
        Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-vec) and ipilimumab (Ipi) in previously untreated, unresected stage IIIB-IV melanoma.
        J Clin Oncol. 2014; 32: 9029
        • Regeneron P.
        A phase 1 study of pre-operative cemiplimab (Regn2810), administered intralesionally, for patients with recurrent cutaneous squamous cell carcinoma(Cscc). Clinical trial registration. 2021. NCT03889912.
        (Available at:) (Accessed July 15, 2021)
        • Middleton M.R.
        • Sacco J.J.
        • Merchan J.R.
        • et al.
        An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
        J Clin Oncol. 2019; 37: TPS2671
        • D'Angelo S.P.
        • Russell J.
        • Lebbé C.
        • et al.
        Efficacy and safety of first-line avelumab treatment in patients with stage iv metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial.
        JAMA Oncol. 2018; 4: e180077
        • D'Angelo S.P.
        • Bhatia S.
        • Brohl A.S.
        • et al.
        Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
        J Immunother Cancer. 2020; 8: e000674
        • Nghiem P.
        • Bhatia S.
        • Lipson E.J.
        • et al.
        Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
        J Immunother Cancer. 2021; 9: e002478
        • Grignani G.
        • Rutkowski P.
        • Lebbe C.
        • et al.
        545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (Mcc) (POD1UM-201).
        J Immunother Cancer. 2021; 9: A574-A575
        • Glutsch V.
        • Kneitz H.
        • Gesierich A.
        • et al.
        Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.
        Cancer Immunol Immunother. 2021; 70: 2087-2093
        • Ota S.
        • Sakamoto T.
        • Ochiai R.
        • et al.
        Successful treatment with taxane-based chemotherapy in advanced sebaceous carcinoma: a case report and literature review.
        Case Rep Oncol. 2019; 12: 47-52
        • Kodali S.
        • Tipirneni E.
        • Gibson P.C.
        • et al.
        Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.
        Ophthalmic Plast Reconstr Surg. 2018; 34: e149-e151
        • Banerjee N.
        • Hossain F.
        • Wirtschafter E.
        • et al.
        Pembrolizumab in the treatment of microsatellite instability-high sebaceous carcinoma: a case report with review of the literature.
        JCO Precis Oncol. 2020; 4: 61-65
        • Chen H.
        • Liu Y.
        • Peng F.
        • et al.
        Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report.
        Ann Transl Med. 2019; 7: 149
        • Rutkowski P.
        • Van Glabbeke M.
        • Rankin C.J.
        • et al.
        Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
        J Clin Oncol. 2010; 28: 1772-1779
        • Jaal J.
        • Putnik K.
        Induction cisplatin-based chemotherapy and following radiotherapy in locally advanced basal cell carcinoma of the skin.
        Acta Oncol. 2012; 51: 952-954
        • Shin D.M.
        • Glisson B.S.
        • Myers J.
        • et al.
        Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.
        J Clin Oncol. 2002; 20: 364-370
        • Nottage M.K.
        • Lin C.
        • Hughes B.G.M.
        • et al.
        Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin.
        Head Neck. 2017; 39: 679-683
        • Foote M.C.
        • McGrath M.
        • Guminski A.
        • et al.
        Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.
        Ann Oncol. 2014; 25: 2047-2052
        • Rischin D.
        • Migden M.R.
        • Lim A.M.
        • et al.
        Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
        J Immunother Cancer. 2020; 8 (Original research): e000775
        • Migden M.R.
        • Khushalani N.I.
        • Chang A.L.S.
        • et al.
        Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
        Lancet Oncol. 2020; 21: 294-305
        • Grob J.-J.
        • Gonzalez R.
        • Basset-Seguin N.
        • et al.
        Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629).
        J Clin Oncol. 2020; 38: 2916-2925